Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
38.93
+2.32 (6.34%)
At close: Sep 26, 2025, 4:00 PM EDT
38.95
+0.02 (0.05%)
After-hours: Sep 26, 2025, 7:39 PM EDT
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.46M in the quarter ending June 30, 2025, with 44.57% growth. This brings the company's revenue in the last twelve months to $40.88M, up 30.57% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$40.88M
Revenue Growth
+30.57%
P/S Ratio
54.63
Revenue / Employee
$83,760
Employees
488
Market Cap
2.26B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AGIO News
- 9 days ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 12 days ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
- 19 days ago - Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive - Seeking Alpha
- 23 days ago - Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
- 23 days ago - FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
- 23 days ago - Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - GlobeNewsWire
- 7 weeks ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript - Seeking Alpha